Skip to main content
. 2020 Feb 20;9(2):492. doi: 10.3390/cells9020492

Table 2.

Clinicopathological features of glioma patients and association with MTAP expression.

MTAP Expression
Total (%) Negative (%) Positive (%) p-Value
Gender (N = 491)
Male
300 (61.1) 141 (47.0) 159 (53.0) 0.503
Female 191 (38.9) 83 (43.5) 108 (56.5)
Age group (N = 504)
0–19 49 (9.7) 26 (53.1) 23 (46.9) 0.479
20–59 256 (50.8) 112 (43.8) 144 (56.2)
>59 199 (39.5) 92 (46.2) 107 (53.8)
Location (N = 210)
Frontal Lobe 88 (41.9) 24 (27.3) 64 (72.7) 0.013
Parietal Lobe 41 (19.5) 9 (22.0) 32 (78.0)
Temporal Lobe 66 (31.4) 28 (42.4) 38 (57.6)
Occipital Lobe 10 (4.8) 5 (50.0) 5 (50.0)
Cerebellum 5 (2.4) 4 (80.0) 1 (20.0)
KPS (N = 168)
<70 75 (44.6) 11 (14.7) 64 (85.3) 0.539
>70 93 (55.4) 18 (19.4) 75 (80.6)
Grade (N = 507)
Low Grade 18 (3.6) 5 (27.8) 13 (72.2) 0.149
High Grade 489 (96.4) 228 (46.6) 261 (53.4)
Histologic Subtype (N = 507)
DA (WHO Grade II, NOS) 18 (3.6) 5 (27.8) 13 (72.2) 0.272
AA (WHO Grade III, NOS) 24 (4.7) 12 (50.0) 12 (50.0)
Ped. GBM (WHO Grade IV, NOS) 42 (8.3) 23 (54.8) 19 (45.2)
Ad. GBM (WHO Grade IV, NOS) 423 (83.4) 193 (45.6) 230 (54.4)
GBM status mutation (N = 460)
IDH1 mutation (N = 229)
No 220 (96.1) 117 (53.2) 103 (46.8) 0.185
Yes 9 (3.9) 7 (77.8) 2 (22.2)
TERT promoter mutation (N = 45)
No 11 (24.4) 3 (27.3) 8 (72.7) 0.687
Yes 34 (75.6) 7 (20.6) 27 (79.4)
MGMT promoter methylation (N = 186)
No 120 (64.5) 75 (62.5) 45 (37.5) 0.753
Yes 66 (35.5) 39 (59.1) 27 (40.9)

Abbreviation: DA: diffuse astrocytoma, AA: anaplastic astrocytoma, Ped. GBM: pediatric glioblastoma, Ad. GBM: adult glioblastoma KPS: Karnofsky Performance Status, NOS: not otherwise specified. T-test (p < 0.05).